Related Experiment Video

Updated: Jun 21, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.1K

YTH domain family protein 3 accelerates non-small cell lung cancer immune evasion through targeting CD8+ T

Yisheng Luo1, Chao Zeng2, Zezhong Ouyang1

  • 1Department of Thoracic Surgery, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, 518000, Guangdong Province, China.

Cell Death Discovery
|July 11, 2024
PubMed

Insights

N6-methyladenosine (m6A) reader YTHDF3 promotes non-small cell lung cancer (NSCLC) immune evasion by enhancing PD-L1 stability. YTHDF3 impairs CD8+ T cell activity, offering potential immunotherapy targets for NSCLC.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Immune evasion is a key characteristic of non-small cell lung cancer (NSCLC).
  • N6-methyladenosine (m6A) modifications are increasingly recognized for their role in NSCLC immune evasion.

Purpose of the Study:

  • To investigate the function and mechanism of the m6A reader YTH domain family protein 3 (YTHDF3) in NSCLC immune evasion.

Main Methods:

  • Analysis of YTHDF3 expression in NSCLC tissues.
  • Functional assays assessing the impact of YTHDF3 up-regulation and silencing on CD8+ T cell activity and apoptosis.
  • Mechanistic studies to identify downstream targets of YTHDF3, including PD-L1 mRNA stability.

Main Results:

  • YTHDF3 is highly expressed in NSCLC and serves as an independent prognostic factor.
  • YTHDF3 up-regulation suppresses CD8+ T cell antitumor activity and NSCLC cell apoptosis.
  • YTHDF3 enhances PD-L1 mRNA transcription stability, promoting immune evasion.
  • YTHDF3 targets PD-L1 to facilitate NSCLC immune evasion by reducing CD8+ T cell-mediated killing.

Conclusions:

  • YTHDF3 promotes NSCLC immune evasion by targeting PD-L1 and impairing CD8+ T cell antitumor immunity.
  • This study provides insights into m6A modification's role in NSCLC antitumor immunity.
  • YTHDF3 may represent a novel target for lung cancer immunotherapy.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

6.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
886
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K